Biotech · Private company
Indapta Therapeutics, INC.
Track this companyFree. Adds Indapta Therapeutics, INC. to your Dealase workspace and tells you when its record changes.
Clinical trials21 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- CyclophosphamidePhase 2 · NHLClinicalTrials.gov · fetched Nov 12, 2026
- DaratumumabPhase 2 · NHLClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 2 · NHLClinicalTrials.gov · fetched Nov 12, 2026
- IDP-023Phase 2 · NHLClinicalTrials.gov · fetched Nov 12, 2026
- Interleukin-2Phase 2 · NHLClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 2 · NHLClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 1 · Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 1 · Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- IDP-023Phase 1 · Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- Interleukin-2Phase 1 · Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- MesnaPhase 1 · Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- OcrelizumabPhase 1 · Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple SclerosisPHASE1 · SUSPENDED · started Jun 30, 2026ClinicalTrials.gov NCT06677710 · fetched Nov 12, 2026
- IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersPHASE1_PHASE2 · RECRUITING · started Oct 25, 2023ClinicalTrials.gov NCT06119685 · fetched Nov 12, 2026